Scandinavian ChemoTech's Animal Care division receives additional order from existing customer
In the past six months, Vetiqure AB has achieved great success in its launch work of the vetIQure™ TSE system around the world for the treatment of superficial tumours in dogs, cats, and horses. The Company has now received another order of 6,000 EUR from an equine hospital in Sweden.
Although this individual order may be seen as small, based on the order value, it reinforces an already established trend. Since vetIQure was launched, its gentler qualities have been proven and are now appreciated by veterinarians around the world. 14 vetIQure systems are now actively being used on the market and you can find them installed in no less than three university hospitals (Great Britain, Australia, and Turkey) and five large veterinary groups in both the EU and the USA. The trend also shows a clear increase in the frequency of use of the vetIQure systems.
"Our goal for the next two years is to be able to double the number of installed systems every year and to publish more case studies to further increase and spread the knowledge about our technology" - says Mohan Frick CEO of ChemoTech and Vetiqure.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: [email protected]
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.